Related Experiment Video
Updated: May 13, 2025
Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019
Evolving Strategies in the Detection and Management of Left Ventricular Thrombus: A Clinical Summary
Mahmoud Abdelnabi1, Ramzi Ibrahim1, Hoang Nhat Pham2
1Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Insights
Left ventricular thrombi (LVT) understanding has advanced, but prevention and management strategies, especially in nonischemic conditions, require more research. Personalized risk assessment is crucial until further evidence emerges for optimal LVT care.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Thrombosis Research
Background:
- Left ventricular thrombi (LVT) prevalence has decreased due to early percutaneous interventions in acute myocardial infarction.
- Optimal strategies for LVT prevention, risk stratification, and management remain unclear, particularly in nonischemic cardiomyopathy.
Purpose of the Study:
- To review advancements in LVT epidemiology and therapeutic options.
- To provide an overview of diagnostic and therapeutic implications of LVT in both ischemic and non-ischemic cardiomyopathies.
Main Methods:
- Literature review of recent advancements in understanding LVT.
- Analysis of diagnostic and therapeutic implications across different cardiomyopathy types.
Main Results:
- Significant evidence gaps persist regarding optimal LVT screening timing and prophylactic anticoagulation.
- Understanding unique risk factors is needed for comprehensive LVT risk quantification and prevention algorithms.
Conclusions:
- Current evidence necessitates individualized LVT screening, prevention, and management based on patient-specific risk factors.
- Prospective cohort studies are needed to address evidence gaps in LVT management and prevention.
Abstract:
Recent advancements have emerged in understanding the epidemiology and optimal therapeutic options for left ventricular thrombi (LVT). With early percutaneous interventions in acute myocardial infarction, the prevalence of LVT has decreased. However, the best strategies for prevention, risk stratification, and management remain unclear, especially among nonischemic cardiomyopathy disorders. This review outlines these advancements and provides an overview of the diagnostic and therapeutic implications of LVT in ischemic and non-ischemic cardiomyopathies. Significant gaps in the current evidence persist, particularly regarding the optimal timing for LVT screening and the need for prophylactic anticoagulation, highlighting opportunities for prospective cohort studies. Furthermore, a better understanding of the unique risk factors that contribute to increased LVT risk would lead to more comprehensive algorithms that may quantify the risk of LVT development, aiding in developing preventive strategies targeted at reducing rates of LVT. Until more definitive evidence is available, clinicians should custom LVT screening, preventive measures, and management strategies based on individual patient risk factors.
